Trial Profile
A randomized clinical trial to study whether telbivudine can decrease the hepatitis B virus reactivation in patients with hepatocellular carcinoma and HBV-DNA < 2000 IU/ml after liver resection.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 28 Nov 2014 New trial record